Caron A. Jacobson, MD, on What Patients Should Know About the Phase 2 ZUMA-5 Study

The expert in hematology discussed what patients should know about the study, which evaluated the use of axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

In an interview with CancerNetwork®, Caron A. Jacobson, MD, of the Dana-Farber Cancer Institute, explained the possible benefits of axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

Results from the interim analysis of the phase 2 ZUMA-5 study, presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, suggested that axi-cel demonstrated significant and durable clinical benefit in this patient population.

Though this particular study requires further follow-up, the investigators suggested that axi-cel may be a promising therapeutic approach for this patient population.


So, I would say that this is a one-time therapy that has a very, very high response rate, meaning that patients’ disease gets better after the single infusion of these CAR T-cells, with over 80% of patients actually entering remission and, we need more time to follow these patients, but with the, you know, with follow up now out to 15.3 months, a lot of these remissions seem to be durable and lasting. And that that, you know, that we hope that that translates into people living longer and even potentially being cured of their disease. And on the flip side of that, we worry about safety. Obviously, whenever we're testing a new therapy and the safety profile appears to be manageable and reversible and self-limited… So, you know, it's a win-win.

Related Videos
Polatuzumab vedotin-piiq plus R-CHP can reduce the need for any subsequent lines of therapy for patients with diffuse large B-cell lymphoma, according to an expert from The University of Texas MD Anderson Cancer Center.
Combining bispecific antibodies with other agents such as R-CHOP and R-CHP for various subtypes of lymphoma has the potential to produce exciting results, according to an expert from Dana-Farber Cancer Institute.
Kami J. Maddocks, MD, Shows Optimism for Future Development of Cellular Therapies in Lymphoma
Kami J. Maddocks, MD, Reviews Ongoing Research Into Bispecific Antibodies and Other New Treatment Combinations for Lymphoma
Kami J. Maddocks, MD, Talks Updates in Hodgkin Lymphoma Using Brentuximab Vedotin and PD-1 Inhibitors
Related Content